1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sailong Pharmaceutical Group Co., Ltd. Class A

Sailong Pharmaceutical Group Co., Ltd. Class A

SSZSE:002898
0.37
CNY
-0.01
(-2.63%)
-0.58EPS
2.03BMarket Cap
Sailong Pharmaceutical Group Co., Ltd. Class A
SZSE:002898
(Shenzhen Stock Exchange)

Recent

price

0.37

P/E

ratio

- -

div

yld

8.64%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.89
1.51
1.88
1.94
2.55
2.48
1.67
0.69
1.4
1.5
1.77
1.5
2.95
3.45
Revenue per Share
0.39
0.24
0.5
0.46
0.45
0.35
0.16
-0.38
-0.13
-0.21
0.05
-0.19
-0.69
-0.59
Basic EPS, GAAP
0.51
0.13
- -
0.21
-0.06
-0.75
-0.9
-0.36
0.02
-0.06
0.03
-0.42
-0.02
- -
Free Cash Flow per Basic Share
0.26
0.28
0.37
0.2
0.1
0.09
0.19
0.07
0.04
0.05
0.03
0.05
0.04
0.03
Dividend per Share
19.14
24.02
1.62
1.93
3.51
3.77
3.74
3.34
3.2
2.99
3.04
2.84
2.16
2.11
Book Value per Share
18.48
15.55
1.25
1.57
3.22
3.43
3.21
2.78
2.61
2.4
2.4
2.13
1.56
1.52
Tangible Book Value per Share
117
118
126
132
143
176
176
176
176
176
176
176
176
176
Basic Weighted Avg Shares
221
178
237
256
364
436
293
121
247
264
311
264
519
608
Sales/Revenue/Turnover
37.11
15.68
29.1
27.04
21.15
16.8
11.24
-60.95
-6.74
-9.9
3.75
-2.9
-3.95
-0.47
Operating Margin (%)
4
5
6
8
10
14
20
29
33
34
33
34
54
- -
Depreciation Expense
46
28
63
61
65
61
27
-67
-23
-37
10
-33
-121
-105
Net Income, GAAP
30.09
10.43
22.31
13.35
15.66
12.99
14.72
- -
- -
- -
57.36
- -
- -
- -
Effective Tax Rate (%)
20.73
15.83
26.66
23.94
17.71
13.96
9.37
-55.7
-9.45
-14.12
3.07
-12.58
-23.36
-17.2
Profit Margin (%)
59
54
87
84
364
278
148
51
23
-42
29
-5
-66
-66
Working Capital
- -
- -
- -
- -
- -
- -
- -
30
43
13
25
30
14
12
LT Debt
112
141
213
254
619
664
659
587
564
526
536
499
384
378
Total Equity
- -
15.74
27.25
22.9
14.29
9.35
3.94
- -
- -
- -
1.44
- -
- -
- -
Return on Invested Capital (%)
- -
20.3
34.97
25.62
14.63
9.42
4.1
- -
- -
- -
1.86
- -
- -
- -
Return on Capital (%)
- -
22.33
35.8
26.19
14.78
9.5
4.16
-10.79
-4.06
-6.85
1.8
-6.4
-27.56
-24.02
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
152
115
103
LT Borrowings
9
8
8
LT Finance Leases
- -
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
176
176
176
Market Capitalization
2,013
2,397
2,028

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
211
345
374
Cash, Cash Equivalents & STI
7
61
29
Accounts Receivable, Net
91
94
86
Inventories
88
80
111
Total Current Liabilities
243
410
441
Payables & Accruals
- -
- -
- -
ST Debt
152
115
103
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.94%
-7.74%
-23.06%
Free Cash Flow
1,248.36%
-446.52%
-94.16%
Net Income, GAAP
-71.61%
-62.62%
265.57%
Sales/Revenue/Turnover
18.92%
42.18%
96.82%
Total Cash Common Dividend
-6.91%
-6.35%
-25.45%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
87
63
45
264
2025
54
82
- -
319
519
2026
153
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
-0.03
-0.17
-0.19
2025
-0.01
-0.08
- -
-0.46
-0.69
2026
-0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
0.01
0.01
0.05
2025
0.01
0.01
- -
0.01
0.04
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sailong Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and commercialization of pharmaceutical raw materials, intermediates, and prepared medicines across China. The company's diverse product portfolio features key offerings such as esomeprazole sodium, ornithine aspartate, argatroban, and milrinone, alongside a recently approved chest pain injection, injectable Nicorandil. Their therapeutic focus spans critical health areas including cardiovascular, cerebrovascular, nervous system, and digestive disorders, in addition to anti-infective, anti-bleeding, and analgesic applications. Founded in 2002, this high-tech enterprise centers its operations in Zhuhai, China, emphasizing technological innovation in its product development and nationwide sales network.